Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study

Aims Paclitaxel is a widely used anti‐neoplastic agent but has low oral bioavailability due to gut extrusion by P‐glycoprotein (P‐gp). Oral paclitaxel could be more convenient, less resource intensive, and more tolerable than intravenous administration. Encequidar (HM30181A) is a novel, minimally ab...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	British journal of clinical pharmacology 2021-12, Vol.87 (12), p.4670-4680
Hauptverfasser:	Jackson, Christopher G. C. A., Hung, Tak, Segelov, Eva, Barlow, Paula, Prenen, Hans, McLaren, Blair, Hung, Noelyn Anne, Clarke, Katriona, Chao, Tsu‐Yi, Dai, Ming‐Shen, Yeh, Hsien‐Tang, Cutler, David L., Kramer, Douglas, He, Jimmy, Zhi, Jay, Chan, Wing‐Kai, Kwan, Rudolf, Deva, Sanjeev
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravenous Administration, Oral ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors cancer Cross-Over Studies encequidar HM30181A Humans Neoplasms - chemically induced Neoplasms - drug therapy oral chemotherapy paclitaxel Paclitaxel - administration & dosage p‐glycoprotein taxanes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!